{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:41:42Z","timestamp":1785526902654,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00259-026-07927-x","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:39:17Z","timestamp":1779237557000},"page":"5774-5781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The predictive role of [177Lu]Lu-PSMA-617 SPECT\/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2842-0301","authenticated-orcid":false,"given":"Riccardo","family":"Laudicella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1070-3746","authenticated-orcid":false,"given":"Greta","family":"Celesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1937-9116","authenticated-orcid":false,"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agatino","family":"Micali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Midili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1851-5528","authenticated-orcid":false,"given":"Victorian M","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Piergentili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Ricciardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Brogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Baldari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8029-8692","authenticated-orcid":false,"given":"Irene A","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Minutoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"7927_CR1","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830\u201345. https:\/\/doi.org\/10.1007\/s00259-023-06255-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7927_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, P\u00e9rez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ. VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7927_CR3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fl\u00e9chon A, Wei XX, Mahammedi H, Roubaud G, \u0160tudentov\u00e1 H, Nagarajah J, Mellado B, Montesa-Pino \u00c1, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K. PSMAfore Investigators. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2.","journal-title":"Lancet"},{"key":"7927_CR4","doi-asserted-by":"publisher","first-page":"1483953","DOI":"10.3389\/fonc.2024.1483953","volume":"14","author":"AR Hansen","year":"2025","unstructured":"Hansen AR, Probst S, Beauregard JM, Viglianti BL, Michalski JM, Tagawa ST, Sartor O, Tutrone RF, Oz OK, Courtney KD, Delpassand ES, Nordquist LT, Osman MM, Chi KN, Sparks R, George N, Hawley SM, Wu W, Jensen JD, Fleshner NE. Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial. Front Oncol. 2025;14:1483953. https:\/\/doi.org\/10.3389\/fonc.2024.1483953.","journal-title":"Front Oncol"},{"key":"7927_CR5","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s00259-025-07083-8","volume":"52","author":"R Laudicella","year":"2025","unstructured":"Laudicella R, Bauckneht M, Burger IA, Cacciola A, Fanti S, Farolfi A, Ficarra V, Iagaru A, Liberini V, Pergolizzi S, Santo G, Virgolini I, Minutoli F, Baldari S. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:2723\u201335. https:\/\/doi.org\/10.1007\/s00259-025-07083-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7927_CR6","doi-asserted-by":"publisher","first-page":"102698","DOI":"10.1016\/j.ctrv.2024.102698","volume":"124","author":"M Bauckneht","year":"2024","unstructured":"Bauckneht M, Ciccarese C, Laudicella R, Mosillo C, D\u2019Amico F, Anghelone A, Strusi A, Beccia V, Bracarda S, Fornarini G, Tortora G, Iacovelli R. Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives. Cancer Treat Rev. 2024;124:102698. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102698.","journal-title":"Cancer Treat Rev"},{"key":"7927_CR7","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.2967\/jnumed.125.270979","volume":"66","author":"C Uribe","year":"2025","unstructured":"Uribe C, Iravani A, Savir-Baruch B, Jacene H, Graves SA, Dewaraja YK, Heath CL, Hope TA. Summary: SNMMI\/ACNM Procedure Standard for Posttreatment Imaging of 177Lu-Based Radiopharmaceuticals. J Nucl Med. 2025;66:1528\u201337. https:\/\/doi.org\/10.2967\/jnumed.125.270979.","journal-title":"J Nucl Med"},{"key":"7927_CR8","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1007\/s00259-023-06176-6","volume":"50","author":"H Song","year":"2023","unstructured":"Song H, Ferri V, Duan H, Aparici CM, Davidzon G, Franc BL, Moradi F, Nguyen J, Shah J, Iagaru A. SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT\/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting. Eur J Nucl Med Mol Imaging. 2023;50:2250\u20137. https:\/\/doi.org\/10.1007\/s00259-023-06176-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7927_CR9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2967\/jnumed.124.267955","volume":"65","author":"S Yadav","year":"2024","unstructured":"Yadav S, Lowery B, Tuchayi AM, Jiang F, Saelee R, Aggarwal RR, Juarez R, Flavell RR, Hope TA. Impact of Posttreatment SPECT\/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy. J Nucl Med. 2024;65:1395\u2013401. https:\/\/doi.org\/10.2967\/jnumed.124.267955.","journal-title":"J Nucl Med"},{"key":"7927_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12880-025-01571-x","volume":"25","author":"TO Alkahtani","year":"2025","unstructured":"Alkahtani TO. Investigating the significance of SPECT\/CT-SUV for monitoring 177Lu-PSMA-targeted radionuclide therapy: a systematic review. BMC Med Imaging. 2025;25:28. https:\/\/doi.org\/10.1186\/s12880-025-01571-x.","journal-title":"BMC Med Imaging"},{"key":"7927_CR11","doi-asserted-by":"publisher","unstructured":"Pathmanandavel S, Crumbaker M, Ho B, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Hickey A, Eu P, Stockler M, Martin AJ, Joshua AM, Nguyen A, Emmett L. Evaluation of 177Lu-PSMA-617 SPECT\/CT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination Trial (LuPIN). J Nucl Med. 64:221\u20136. https:\/\/doi.org\/10.2967\/jnumed.122.264398","DOI":"10.2967\/jnumed.122.264398"},{"key":"7927_CR12","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00259-022-06028-9","volume":"50","author":"JC Dickson","year":"2023","unstructured":"Dickson JC, Armstrong IS, Gabi\u00f1a PM, Denis-Bacelar AM, Krizsan AK, Gear JM, Van den Wyngaert T, de Geus-Oei LF, Herrmann K. EANM practice guideline for quantitative SPECT-CT. Eur J Nucl Med Mol Imaging. 2023;50:980\u201395. https:\/\/doi.org\/10.1007\/s00259-022-06028-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7927_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.2967\/jnumed.124.269431","volume":"66","author":"LM Unterrainer","year":"2025","unstructured":"Unterrainer LM, De Leiris N, Unterrainer M, Delker A, Hempel L, Ells Z, Kunte SC, Zahner J, Holzgreve A, Zacherl MJ, Sheikh GT, Casuscelli J, Leenhardt J, Pienta KJ, Jacquet E, Laramas M, Long J, Faure M, Reboulet G, Paller CJ, Mercier A, Solnes LB, Kiraz K, Ilhan H, Gafita A, Djaileb L. Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data. J Nucl Med. 2025;66:1054\u201360. https:\/\/doi.org\/10.2967\/jnumed.124.269431.","journal-title":"J Nucl Med"},{"key":"7927_CR14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.2967\/jnumed.119.233817","volume":"61","author":"S Fanti","year":"2020","unstructured":"Fanti S, Hadaschik B, Herrmann K. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET\/CT Imaging: The PSMA PET Progression Criteria. J Nucl Med. 2020;61:678\u201382. https:\/\/doi.org\/10.2967\/jnumed.119.233817.","journal-title":"J Nucl Med"},{"key":"7927_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00259-024-06856-x","volume":"52","author":"NJ Rupp","year":"2024","unstructured":"Rupp NJ, Freiberger SN, Ferraro DA, Laudicella R, Heimer J, Muehlematter UJ, Poyet C, Moch H, Eberli D, R\u00fcschoff JH, Burger IA. Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2024;52:305\u201313. https:\/\/doi.org\/10.1007\/s00259-024-06856-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7927_CR16","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23:1389\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(22)00605-2.","journal-title":"Lancet Oncol"},{"key":"7927_CR17","doi-asserted-by":"publisher","first-page":"e233460","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K. Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial). Radiology. 2024;312:e233460. https:\/\/doi.org\/10.1148\/radiol.233460.","journal-title":"Radiology"},{"key":"7927_CR18","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.2967\/jnumed.124.267606","volume":"65","author":"M Swiha","year":"2024","unstructured":"Swiha M, Pathmanandavel S, Papa N, Sabahi Z, Li S, Zheng A, Khan S, Ayers M, Sharma S, Crumbaker M, Nguyen A, Chan L, Ayati N, Emmett L. Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT\/CT and Pretherapy PSMA PET\/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024;65:1939\u201344. https:\/\/doi.org\/10.2967\/jnumed.124.267606.","journal-title":"J Nucl Med"},{"key":"7927_CR19","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.2967\/jnumed.124.267665","volume":"65","author":"RA Demirci","year":"2024","unstructured":"Demirci RA, Gulati R, Hawley JE, Yezefski T, Haffner MC, Cheng HH, Montgomery RB, Schweizer MT, Yu EY, Nelson PS, Chen DL, Iravani A. SPECT\/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617. J Nucl Med. 2024;65:1945\u201351. https:\/\/doi.org\/10.2967\/jnumed.124.267665.","journal-title":"J Nucl Med"},{"key":"7927_CR20","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2967\/jnumed.125.269640","volume":"66","author":"R Kashyap","year":"2025","unstructured":"Kashyap R, Buteau JP, Bressel M, Eifer M, Bollampally N, Jackson P, McIntosh L, Sandhu S, Hofman MS. Prognostic Value of Posttherapy SPECT\/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. J Nucl Med. 2025;66:1265\u201370. https:\/\/doi.org\/10.2967\/jnumed.125.269640.","journal-title":"J Nucl Med"},{"key":"7927_CR21","doi-asserted-by":"publisher","first-page":"1291253","DOI":"10.3389\/fnume.2023.1291253","volume":"3","author":"C Meyer","year":"2023","unstructured":"Meyer C, Szidonya L, Winters C, Mench A, Mallak N, Mittra E. Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry. Front Nucl Med. 2023;3:1291253. https:\/\/doi.org\/10.3389\/fnume.2023.1291253","journal-title":"Front Nucl Med."},{"key":"7927_CR22","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.2967\/jnumed.123.267208","volume":"65","author":"S Yadav","year":"2024","unstructured":"Yadav S, Jiang F, Kurkowska S, Saelee R, Morley A, Feng F, Aggarwal R, Lawhn-Heath C, Uribe C, Hope TA. Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection. J Nucl Med. 2024;65:1064\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.267208.","journal-title":"J Nucl Med"},{"key":"7927_CR23","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ijrobp.2025.06.3869","volume":"123","author":"KJ Fitzpatrick","year":"2025","unstructured":"Fitzpatrick KJ, Mikell JK, Roseland ME, Niedbala J, Suresh K, Peterson AB, Viglianti BL, Wong KK, Frey KA, Dewaraja YK. 177Lu-PSMA-617 Single-Photon Emission Computed Tomography\/Computed Tomography Dosimetry and Radiobiological Models Demonstrate Decreasing Tumor-to-Kidney Dose Ratio With Successive Cycles. Int J Radiat Oncol Biol Phys. 2025;123:937\u201346. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.06.3869.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7927_CR24","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2967\/jnumed.125.270170","volume":"66","author":"M Grkovski","year":"2025","unstructured":"Grkovski M, Krebs SS, O\u2019Donoghue JA, Kuten J, Mauguen A, Shobeiri P, Lafontaine D, Thor M, Augensen F, Fox JJ, Pandit-Taskar N, Dunphy MP, Bodei L, Humm JL, Sch\u00f6der H. Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy. J Nucl Med. 2025;66:1622\u201330. https:\/\/doi.org\/10.2967\/jnumed.125.270170.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07927-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:05:40Z","timestamp":1785521140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07927-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7927"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07927-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and approved by the Institutional Review Board (id 02\u201326). The external validation set was approved by the Regional Ethical Committee of Regione Liguria (registration number 5\/2023-DB id 12914).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent to publish has been received from all participants.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}